{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:42:16Z","timestamp":1791477736455,"version":"4.3.4"},"reference-count":69,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["591014"],"award-info":[{"award-number":["591014"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS098228"],"award-info":[{"award-number":["NS098228"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioral Sciences"],"abstract":"<jats:p>Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, and supplements. Associations were assessed at p &lt; 0.05 and p &lt; 0.001 significance thresholds using applicable methods (Chi-square, t-test, ANOVA, logistical regression, random forests, Fisher\u2019s exact test) within a retrospective cohort of 1585 patients. Factors significantly correlated with positive (happy or normal) mood included family support and usage of bi-level positive airway pressure (Bi-PAP) and\/or cough assist. Decline in physical factors like presence of dysphagia, drooling, general pain, and decrease in ALSFRS-R total score or forced vital capacity (FVC) significantly correlated with negative (depressed or anxious) mood (p &lt; 0.05). Use of antidepressants or pain medications had no association with ALS patient mood (p &gt; 0.05), but were significantly associated with increased survival (p &lt; 0.05). Positive patient mood, Bi-PAP, cough assist, percutaneous endoscopic gastrostomy (PEG), and accompaniment to clinic visits associated with increased survival duration (p &lt; 0.001). Of the 47 most prevalent pharmaceutical and supplement categories, 17 associated with significant survival duration increases ranging +4.5 to +16.5 months. Tricyclic antidepressants, non-opioids, muscle relaxants, and vitamin E had the highest associative increases in survival duration (p &lt; 0.05). Random forests, which examined complex interactions, identified the following pharmaceuticals and supplements as most predictive to survival duration: Vitamin A, multivitamin, PEG supplements, alternative herbs, antihistamines, muscle relaxants, stimulant laxatives, and antispastics. Statins, metformin, and thiazide diuretics had insignificant associations with decreased survival.<\/jats:p>","DOI":"10.3390\/bs10010033","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"33","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration"],"prefix":"10.3390","volume":"10","author":[{"given":"Leila","family":"Bond","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mertens","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keelie","family":"Denson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"},{"name":"School of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Vidakovic","sequence":"additional","affiliation":[{"name":"Department of Industrial &amp; Systems Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie S.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Georgia Institute of Technology &amp; Emory University, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2152-7806.169561","article-title":"A comprehensive review of amyotrophic lateral sclerosis","volume":"6","author":"Zarei","year":"2015","journal-title":"Surg. Neurol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_3","unstructured":"National Cancer Institute at the National Institutes of Health (2019, October 20). NCI Dictionary of Cancer Terms, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/quality-of-life."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0269216311429042","article-title":"Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: A prospective cohort study","volume":"27","author":"Lee","year":"2013","journal-title":"Palliat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fneur.2018.00578","article-title":"Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration With Non-invasive Ventilation Initiation and Usage Protocols","volume":"9","author":"Khamankar","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.24202","article-title":"Rehabilitation in amyotrophic lateral sclerosis: Why it matters","volume":"50","author":"Majmudar","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1348\/135910799168524","article-title":"Mood as a predictor of disability and survival in patients newly diagnosed with ALS MND","volume":"4","author":"Johnston","year":"1999","journal-title":"Br. J. Health Psychol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12955-016-0507-6","article-title":"Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: A systematic review","volume":"14","author":"Schroder","year":"2016","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/17482960802566824","article-title":"Prognostic factors in ALS: A critical review","volume":"10","author":"Chio","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/17482960902918719","article-title":"Correlates of quality of life in ALS: Lessons from the minocycline study","volume":"11","author":"Lou","year":"2010","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s13311-014-0322-x","article-title":"Patient-Perceived Outcomes and Quality of Life in ALS","volume":"12","author":"Simmons","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14660820310016066","article-title":"Validation of quality of life instruments in ALS","volume":"5","author":"Bourke","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.apmr.2011.01.025","article-title":"The Neurology Quality-of-Life Measurement Initiative","volume":"92","author":"Cella","year":"2011","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1016704906100","article-title":"Assessing individual quality of life in amyotrophic lateral sclerosis","volume":"10","author":"Clarke","year":"2001","journal-title":"Qual. Life Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17482960802163721","article-title":"Quality of life in amyotrophic lateral sclerosis\/motor neuron disease: A structured review","volume":"10","author":"Epton","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/17482960802444840","article-title":"The SEIQoL-DW for assessing quality of life in ALS: Strengths and limitations","volume":"10","author":"Felgoise","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/146608299300080022","article-title":"Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40","volume":"1","author":"Jenkinson","year":"1999","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/03033910.1997.10558129","article-title":"Quality of Life assessment: A paradigm shift in healthcare?","volume":"18","year":"1997","journal-title":"Ir. J. Psychol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bond, L., Ganguly, P., Khamankar, N., Mallet, N., Bowen, G., Green, B., and Mitchell, C.S. (2019). A Comprehensive Examination of Percutaneous Endoscopic Gastrostomy and Its Association with Amyotrophic Lateral Sclerosis Patient Outcomes. Brain Sci., 9.","DOI":"10.3390\/brainsci9090223"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/bmj.322.7298.1357","article-title":"Measuring quality of life\u2014Are quality of life measures patient centred?","volume":"322","author":"Carr","year":"2001","journal-title":"Br. Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/jnnp.2003.033100","article-title":"A cross sectional study on determinants of quality of life in ALS","volume":"75","author":"Chio","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_23","first-page":"84","article-title":"Amyotrophic lateral sclerosis: A consensus viewpoint on designing and implementing a clinical trial","volume":"5","author":"Leigh","year":"2004","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/146608200300079464","article-title":"Improving the quality of life for people with ALS: The challenge ahead","volume":"1","author":"Mitsumoto","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1212\/WNL.56.4.442","article-title":"Quality of life in ALS is maintained as physical function declines","volume":"56","author":"Robbins","year":"2001","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.biopsych.2012.03.015","article-title":"Vocal acoustic biomarkers of depression severity and treatment response","volume":"72","author":"Mundt","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Williamson, J.R., Quatieri, T.F., Helfer, B.S., Horwitz, R., Yu, B., and Mehta, D.D. (2013, January 21\u201325). Vocal biomarkers of depression based on motor incoordination. Proceedings of the 3rd ACM International Workshop on Audio\/Visual Emotion Challenge, Barcelona, Spain.","DOI":"10.1145\/2512530.2512531"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/pon.3275","article-title":"Does awareness of terminal status influence survival and quality of life in terminally ill cancer patients?","volume":"22","author":"Kim","year":"2013","journal-title":"Psychooncology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/17482960701374643","article-title":"Psychological health in patients with amyotrophic lateral sclerosis","volume":"8","author":"Averill","year":"2007","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/17482968.2011.554555","article-title":"Psychological health in patients with ALS is maintained as physical function declines","volume":"12","author":"Cupp","year":"2011","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1152\/jn.00425.2013","article-title":"Effect of fluoxetine on disease progression in a mouse model of ALS","volume":"111","author":"Koschnitzky","year":"2014","journal-title":"J. Neurophysiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1460-9568.2007.05663.x","article-title":"Nortriptyline delays disease onset in models of chronic neurodegeneration","volume":"26","author":"Wang","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2013.06.033","article-title":"Neuroprotective and procognitive effects of sertraline: In vitro and in vivo studies","volume":"550","author":"Taler","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115490","DOI":"10.18632\/oncotarget.23302","article-title":"Antidepressants, sertraline and paroxetine, increase calcium influx and induce mitochondrial damage-mediated apoptosis of astrocytes","volume":"8","author":"Then","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Then, C.K., Chi, N.F., Chung, K.H., Kuo, L., Liu, K.H., Hu, C.J., Shen, S.C., and Lin, Y.K. (2017). Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175187"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fneur.2016.00047","article-title":"Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom?","volume":"7","author":"Hollinger","year":"2016","journal-title":"Front. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000369812","article-title":"Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis","volume":"15","author":"Mitchell","year":"2015","journal-title":"Neurodegener. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/21678421.2018.1511731","article-title":"Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly","volume":"19","author":"Freedman","year":"2018","journal-title":"Amyotroph. Lateral. Scler Front. Degener."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40264-017-0620-4","article-title":"Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA\u2019s Adverse Event Reporting System","volume":"41","author":"Golomb","year":"2018","journal-title":"Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1468-1331.2008.02102.x","article-title":"Morphine in the management of dyspnoea in ALS. A pilot study","volume":"15","author":"Clemens","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_42","first-page":"1139","article-title":"Anesthetic management of an ALS patient with remifentanil","volume":"57","author":"Umegaki","year":"2008","journal-title":"Masui"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/21678421.2015.1074701","article-title":"Pain in amyotrophic lateral sclerosis: Patient and physician perspectives and practices","volume":"17","author":"Stephens","year":"2015","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_44","first-page":"A56","article-title":"Undergraduate Biocuration: Developing Tomorrow\u2019s Researchers While Mining Today\u2019s Data","volume":"14","author":"Mitchell","year":"2015","journal-title":"J. Undergrad. Neurosci. Educ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fninf.2018.00036","article-title":"Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction","volume":"12","author":"Pfohl","year":"2018","journal-title":"Front. Neuroinform."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Strobl, C., Boulesteix, A.L., Zeileis, A., and Hothorn, T. (2007). Bias in random forest variable importance measures: Illustrations, sources and a solution. BMC Bioinform., 8.","DOI":"10.1186\/1471-2105-8-25"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Korner, S., Kollewe, K., Abdulla, S., Zapf, A., Dengler, R., and Petri, S. (2015). Interaction of physical function, quality of life and depression in Amyotrophic lateral sclerosis: Characterization of a large patient cohort. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0340-2"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1021686606648","article-title":"Quality of life and neurological illness: A review of the literature","volume":"9","author":"Murrell","year":"1999","journal-title":"Neuropsychol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jns.2005.05.018","article-title":"Individual and health-related quality of life assessment in amyotrophic lateral sclerosis patients and their caregivers","volume":"238","author":"Cicero","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/01.wnl.0000257093.53430.a8","article-title":"A longitudinal study on quality of life and depression in ALS patient-caregiver couples","volume":"68","author":"Gauthier","year":"2007","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1212\/WNL.57.11.2040","article-title":"Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS","volume":"57","author":"Bourke","year":"2001","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.nrl.0000178758.30374.34","article-title":"Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death","volume":"11","author":"Simmons","year":"2005","journal-title":"Neurologist"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Burkhardt, C., Neuwirth, C., Sommacal, A., Andersen, P.M., and Weber, M. (2017). Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177555"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuropharm.2018.11.015","article-title":"Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat","volume":"146","author":"Smith","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000433581","article-title":"An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies","volume":"15","author":"Coan","year":"2015","journal-title":"Neurodegener. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.wnl.0000503501.75283.f1","article-title":"Depression in ALS in a large self-reporting cohort Author Response","volume":"87","author":"Kawada","year":"2016","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1212\/WNL.0000000000002465","article-title":"Depression in ALS in a large self-reporting cohort","volume":"86","author":"Thakore","year":"2016","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"403808","DOI":"10.1155\/2011\/403808","article-title":"Pain in amyotrophic lateral sclerosis: A neglected aspect of disease","volume":"2011","author":"Handy","year":"2011","journal-title":"Neurol. Res. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2006.00377.x","article-title":"Reduced oxidative damage in ALS by high-dose enteral melatonin treatment","volume":"41","author":"Weishaupt","year":"2006","journal-title":"J. Pineal Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fnins.2018.00010","article-title":"A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy","volume":"12","author":"Bond","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/(SICI)1097-4598(199803)21:3<336::AID-MUS7>3.0.CO;2-B","article-title":"Fasciculation potentials: A study of amyotrophic lateral sclerosis and other neurogenic disorders","volume":"21","author":"Swash","year":"1998","journal-title":"Muscle Nerve"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.clinph.2013.10.052","article-title":"Complex fasciculation potentials and survival in amyotrophic lateral sclerosis","volume":"125","author":"Shimizu","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1049909109338937","article-title":"Diphenhydramine may be useful as a palliative treatment for patients dying with Parkinson\u2019s disease and tremors: A case report and discussion","volume":"26","author":"Gonzalez","year":"2009","journal-title":"Am. J. Hosp. Palliat Care"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kaneb, H.M., Sharp, P.S., Rahmani-Kondori, N., and Wells, D.J. (2011). Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024189"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000008180","article-title":"Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis","volume":"43","author":"Scelsa","year":"2000","journal-title":"Eur. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02291141","article-title":"Amyotrophic lateral sclerosis with hypertensive attacks: Blood pressure changes in response to drug administration","volume":"6","author":"Shimizu","year":"1996","journal-title":"Clin. Auton Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fncel.2015.00248","article-title":"Seeking homeostasis: Temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice","volume":"9","author":"Irvin","year":"2015","journal-title":"Front. Cell Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12839","DOI":"10.1111\/acel.12839","article-title":"SIRT1 deacetylase in aging-induced neuromuscular degeneration and amyotrophic lateral sclerosis","volume":"17","author":"Herskovits","year":"2018","journal-title":"Aging Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10571-016-0452-2","article-title":"Could Sirtuin Activities Modify ALS Onset and Progression?","volume":"37","author":"Tang","year":"2017","journal-title":"Cell Mol. Neurobiol."}],"container-title":["Behavioral Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-328X\/10\/1\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:04:25Z","timestamp":1760364265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-328X\/10\/1\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["bs10010033"],"URL":"https:\/\/doi.org\/10.3390\/bs10010033","relation":{},"ISSN":["2076-328X"],"issn-type":[{"value":"2076-328X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]}}}